KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clover Health Investments (CLOV) Total Non-Current Liabilities (2020 - 2025)

Clover Health Investments (CLOV) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $193.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 31.39% year-over-year to $193.4 million, compared with a TTM value of $193.4 million through Sep 2025, down 31.39%, and an annual FY2024 reading of $213.5 million, down 18.23% over the prior year.
  • Total Non-Current Liabilities was $193.4 million for Q3 2025 at Clover Health Investments, down from $201.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $2.2 billion in Q1 2022 and bottomed at $84.1 million in Q2 2024.
  • Average Total Non-Current Liabilities over 5 years is $532.4 million, with a median of $355.4 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities soared 907.98% in 2022, then plummeted 81.71% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $396.7 million in 2021, then increased by 9.8% to $435.5 million in 2022, then tumbled by 40.05% to $261.1 million in 2023, then dropped by 18.23% to $213.5 million in 2024, then dropped by 9.4% to $193.4 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CLOV at $193.4 million in Q3 2025, $201.9 million in Q2 2025, and $215.7 million in Q1 2025.